Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3033(2)] to Butyrylcholinesterase
- Suitable for: WB
- Reacts with: Human
Product nameAnti-Butyrylcholinesterase antibody [EPR3033(2)]
See all Butyrylcholinesterase primary antibodies
DescriptionRabbit monoclonal [EPR3033(2)] to Butyrylcholinesterase
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC,IHC-P or IP
Species reactivityReacts with: Human
Synthetic peptide within Human Butyrylcholinesterase aa 550-650 (C terminal). The exact sequence is proprietary.
- A375, HeLa and 293T cell lysates.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20ºC.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab151554 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 68 kDa.|
FunctionEsterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Tissue specificityDetected in blood plasma (at protein level). Present in most cells except erythrocytes.
Involvement in diseaseDefects in BCHE are the cause of butyrylcholinesterase deficiency (BChE deficiency) [MIM:177400]. BChE deficiency is a metabolic disorder characterized by prolonged apnoea after the use of certain anesthetic drugs, including the muscle relaxants succinylcholine or mivacurium and other ester local anesthetics. The duration of the prolonged apnoea varies significantly depending on the extent of the enzyme deficiency. BChE deficiency is a multifactorial disorder. The hereditary condition is transmitted as an autosomal recessive trait.
Sequence similaritiesBelongs to the type-B carboxylesterase/lipase family.
- Information by UniProt
- Acylcholine acylhydrolase antibody
- BCHE antibody
- Butyrylcholine esterase antibody
ab151554 has not yet been referenced specifically in any publications.